X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Merck Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs MERCK LTD - Comparison Results

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA MERCK LTD AJANTA PHARMA/
MERCK LTD
 
P/E (TTM) x 24.6 33.2 74.1% View Chart
P/BV x 10.1 3.7 273.1% View Chart
Dividend Yield % 0.6 0.8 77.7%  

Financials

 AJANTA PHARMA   MERCK LTD
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
MERCK LTD
Dec-16
AJANTA PHARMA/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs1,7201,060 162.3%   
Low Rs1,103623 177.0%   
Sales per share (Unadj.) Rs194.6632.4 30.8%  
Earnings per share (Unadj.) Rs45.245.7 98.9%  
Cash flow per share (Unadj.) Rs50.362.3 80.7%  
Dividends per share (Unadj.) Rs8.0011.00 72.7%  
Dividend yield (eoy) %0.61.3 43.4%  
Book value per share (Unadj.) Rs132.0388.8 34.0%  
Shares outstanding (eoy) m88.7716.60 534.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.31.3 545.1%   
Avg P/E ratio x31.218.4 169.6%  
P/CF ratio (eoy) x28.113.5 207.8%  
Price / Book Value ratio x10.72.2 494.0%  
Dividend payout %17.724.1 73.5%   
Avg Mkt Cap Rs m125,29913,969 897.0%   
No. of employees `000NA1.6 0.0%   
Total wages/salary Rs m2,5701,487 172.9%   
Avg. sales/employee Rs ThNM6,631.9-  
Avg. wages/employee Rs ThNM939.2-  
Avg. net profit/employee Rs ThNM479.4-  
INCOME DATA
Net Sales Rs m17,27510,498 164.6%  
Other income Rs m166242 68.6%   
Total revenues Rs m17,44210,741 162.4%   
Gross profit Rs m5,8071,135 511.5%  
Depreciation Rs m451276 163.6%   
Interest Rs m490-   
Profit before tax Rs m5,4741,102 496.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,460343 425.3%   
Profit after tax Rs m4,014759 528.9%  
Gross profit margin %33.610.8 310.8%  
Effective tax rate %26.731.1 85.6%   
Net profit margin %23.27.2 321.4%  
BALANCE SHEET DATA
Current assets Rs m7,6396,410 119.2%   
Current liabilities Rs m2,7158,828 30.7%   
Net working cap to sales %28.5-23.0 -123.7%  
Current ratio x2.80.7 387.6%  
Inventory Days Days4358 74.9%  
Debtors Days Days7938 204.9%  
Net fixed assets Rs m6,9141,406 491.6%   
Share capital Rs m177166 106.6%   
"Free" reserves Rs m11,4426,286 182.0%   
Net worth Rs m11,7216,455 181.6%   
Long term debt Rs m1490-   
Total assets Rs m14,8148,828 167.8%  
Interest coverage x112.9NM-  
Debt to equity ratio x00-  
Sales to assets ratio x1.21.2 98.1%   
Return on assets %27.48.6 319.0%  
Return on equity %34.211.8 291.3%  
Return on capital %46.517.1 272.5%  
Exports to sales %55.18.3 665.9%   
Imports to sales %6.021.0 28.5%   
Exports (fob) Rs m9,527869 1,095.8%   
Imports (cif) Rs m1,0382,209 47.0%   
Fx inflow Rs m10,422959 1,087.0%   
Fx outflow Rs m1,6782,612 64.2%   
Net fx Rs m8,744-1,653 -528.9%   
CASH FLOW
From Operations Rs m3,2641,070 304.9%  
From Investments Rs m-2,093-750 279.2%  
From Financial Activity Rs m-1,186-150 791.5%  
Net Cashflow Rs m-15171 -8.7%  

Share Holding

Indian Promoters % 73.8 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 1.6 18.2 8.5%  
FIIs % 7.6 1.0 760.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 29.1 58.4%  
Shareholders   20,968 28,591 73.3%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   BIOCON LTD  WOCKHARDT LTD.  SHASUN PHARMA  STRIDES SHASUN LTD  J.B.CHEMICALS  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Day Flat; Oil and Gas Stocks Lead Losses(Closing)

After opening the day in red, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Feb 22, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS